Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors

AIDS

Volumn 17, Issue 13, 2003, Pages 1889-1896

  Sirivichayakul, Sunee ^a,b   Ruxrungtham, Kiat ^a,b,f   Ungsedhapand, Chaiwat ^b   Techasathit, Wichai ^c   Ubolyam, Sasiwimol ^b   Chuenyam, Theshinee ^b   Emery, Sean ^d   Cooper, David ^b   Lange, Joep ^b,e   Phanuphak, Praphan ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Natl AIDS Therapy Evaluation Centre   (Netherlands)

^f THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Abacavir; Didanosine; Genotypic resistance; HIV 1 subtype A E; Lamivudine; Nucleoside reverse transcriptase inhibitors; Stavudine; Zidovudine

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LEUCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENE SWITCHING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS GENE; VIRUS MUTATION; VIRUS STRAIN;

ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 0042329128     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309050-00007     Document Type: Article

References (15)

1. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181:358-363.
2. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000, 14:761-770.
3. Yeni PG, Hammers SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
4. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
5. D' Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. International AIDS Society-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Topics in HIV Med 2002, 10:21-25.
6. Phanuphak P, Cooper DA, Lange J. Clinical trials in Asia. AIDS 1998, 12(suppl. B):S163-S167.
7. Ruxrungtham K, Kroon EDMB, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naïve, HIV-infected Thai patients. AIDS 2000, 14:1375-1382.
8. Ungsedhapand C, Kroon EDMB, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naïve HIV-infected Thai patients. J Acquir Immune Def Syndr 2001, 27:116-123.
9. Ubolyam S, Ruxrungtham K, Sirivichayakul S, Okuda K, Phanuphak P. Evidence of three HIV-1 subtypes in subgroups of individuals in Thailand. Lancet 1994, 344:485-486.
10. Sirivichayakul S, Chantratita W, Sutthent R, Ruxrungtham K, Phanuphak P, Oelrichs RB. Survey of reverse transcriptase from the heterosexual epidemic of human immunodeficiency virus type 1 CRF01_AE in Thailand from 1990-2000. AIDS Res Hum Retroviruses 2001, 17:1077-1081.
11. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000, 14:F9-F15.
12. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis 2001, 184:281-284.
13. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, et al. Emergence of zidovudine and multidrug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. AIDS 1999, 13:1705-1709.
14. Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naïve patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001, 17:1107-1115.
15. Ait-Khald M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir Ther 2002, 7:43-51.